IRLAB Therapeutics AB earnings
Annual earnings per share (SEK per share, as reported)
| Fiscal year | Period end | Diluted EPS | Basic EPS | Filed |
|---|---|---|---|---|
| 2024 | 2024-12-31 | SEK -1.60 | SEK -1.60 | 2026-06-19T06:15:23Z |
| 2023 | 2023-12-31 | SEK -3.43 | SEK -3.43 | 2026-06-19T06:15:23Z |
Revenue & profit (SEK)
| Concept | 2024 | 2023 |
|---|---|---|
| Revenue | SEK 94.6M | SEK 5.7M |
| Profit for the year | -SEK 83.1M | -SEK 177.8M |
Methodology
Earnings per share comes from ifrs-full:DilutedEarningsLossPerShare /
ifrs-full:BasicEarningsLossPerShare; revenue from
ifrs-full:Revenue and profit from ifrs-full:ProfitLoss,
as tagged in IRLAB Therapeutics AB's ESEF annual reports (source:
filings.xbrl.org).
Figures are in SEK, as reported. Not investment advice.